The Filings Report

Labcorp Holdings Inc.

LHNYSECIK 920148Healthcare / Healthcare Providers & Servicesfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$3.8B
+6.9% on Q3 FY2025
Net income
$263M
+0.7% on Q3 FY2025
Free cash flow
$412M
+47.0% on Q3 FY2025
Diluted EPS
$3.22
+3.2% on Q3 FY2025
Revenue, TTM
$14.6B
trailing four quarters
Net margin, TTM
6.9%
net income $1.0B
Free cash flow, TTM
$1.3B
$1.8B less $528M capex
Cash and equivalents
$262M
long-term debt $5.3B, Sep 30, 2026
Shares, 12-month change
−2.0%
81M shares, Sep 30, 2026
Buybacks, TTM
$677M
2.3% of market value
Dividends, TTM
$237M
0.8% of market value
Market value
$29.3B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Labcorp Holdings Inc. reported revenue of $3.8B, +6.9% on Q3 FY2025, and net income of $263M (+0.7%). Operating margin was 10.6%. Free cash flow, operating cash flow less capital expenditures, was $412M ($564M less $152M). Diluted earnings per share were $3.22.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 30, 2026.

Revenue and net incomeRevenueNet income
−$1B$0$1B$2B$3B$4BQ4'22, Net income: $76MQ4'22Q1'23, Revenue: $3.0BQ1'23, Net income: $213MQ1'23Q2'23, Revenue: $3.0BQ2'23, Net income: $189MQ2'23Q3'23, Revenue: $3.1BQ3'23, Net income: $183MQ3'23Q4'23, Revenue: $3.0BQ4'23, Net income: −$167MQ4'23Q1'24, Revenue: $3.2BQ1'24, Net income: $228MQ1'24Q2'24, Revenue: $3.2BQ2'24, Net income: $205MQ2'24Q3'24, Revenue: $3.3BQ3'24, Net income: $169MQ3'24Q4'24, Revenue: $3.3BQ4'24, Net income: $143MQ4'24Q1'25, Revenue: $3.3BQ1'25, Net income: $213MQ1'25Q2'25, Revenue: $3.5BQ2'25, Net income: $238MQ2'25Q3'25, Revenue: $3.6BQ3'25, Net income: $261MQ3'25Q4'25, Revenue: $3.5BQ4'25, Net income: $165MQ4'25Q1'26, Revenue: $3.5BQ1'26, Net income: $278MQ1'26Q2'26, Revenue: $3.7BQ2'26, Net income: $299MQ2'26Q3'26, Revenue: $3.8BQ3'26, Net income: $263MQ3'26−$1B$0$1B$2B$3B$4BQ4'22, Net income: $76MQ1'23, Revenue: $3.0BQ1'23, Net income: $213MQ1'23Q2'23, Revenue: $3.0BQ2'23, Net income: $189MQ3'23, Revenue: $3.1BQ3'23, Net income: $183MQ3'23Q4'23, Revenue: $3.0BQ4'23, Net income: −$167MQ1'24, Revenue: $3.2BQ1'24, Net income: $228MQ1'24Q2'24, Revenue: $3.2BQ2'24, Net income: $205MQ3'24, Revenue: $3.3BQ3'24, Net income: $169MQ3'24Q4'24, Revenue: $3.3BQ4'24, Net income: $143MQ1'25, Revenue: $3.3BQ1'25, Net income: $213MQ1'25Q2'25, Revenue: $3.5BQ2'25, Net income: $238MQ3'25, Revenue: $3.6BQ3'25, Net income: $261MQ3'25Q4'25, Revenue: $3.5BQ4'25, Net income: $165MQ1'26, Revenue: $3.5BQ1'26, Net income: $278MQ1'26Q2'26, Revenue: $3.7BQ2'26, Net income: $299MQ3'26, Revenue: $3.8BQ3'26, Net income: $263MQ3'26

Net income losses drawn in red.

Free cash flow
−$250M$0$250M$500M$750MQ4'22, Free cash flow: $555MQ4'22Q1'23, Free cash flow: $43MQ1'23Q2'23, Free cash flow: $248MQ2'23Q3'23, Free cash flow: $171MQ3'23Q4'23, Free cash flow: $412MQ4'23Q1'24, Free cash flow: −$164MQ1'24Q2'24, Free cash flow: $433MQ2'24Q3'24, Free cash flow: $162MQ3'24Q4'24, Free cash flow: $665MQ4'24Q1'25, Free cash flow: −$108MQ1'25Q2'25, Free cash flow: $543MQ2'25Q3'25, Free cash flow: $281MQ3'25Q4'25, Free cash flow: $490MQ4'25Q1'26, Free cash flow: $71MQ1'26Q2'26, Free cash flow: $314MQ2'26Q3'26, Free cash flow: $412MQ3'26−$250M$0$250M$500M$750MQ4'22, Free cash flow: $555MQ1'23, Free cash flow: $43MQ1'23Q2'23, Free cash flow: $248MQ3'23, Free cash flow: $171MQ3'23Q4'23, Free cash flow: $412MQ1'24, Free cash flow: −$164MQ1'24Q2'24, Free cash flow: $433MQ3'24, Free cash flow: $162MQ3'24Q4'24, Free cash flow: $665MQ1'25, Free cash flow: −$108MQ1'25Q2'25, Free cash flow: $543MQ3'25, Free cash flow: $281MQ3'25Q4'25, Free cash flow: $490MQ1'26, Free cash flow: $71MQ1'26Q2'26, Free cash flow: $314MQ3'26, Free cash flow: $412MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6BQ4'22, Cash and equivalents: $321MQ4'22, Long-term debt: $5.0BQ4'22Q1'23, Cash and equivalents: $394MQ1'23, Long-term debt: $5.1BQ1'23Q2'23, Cash and equivalents: $1.9BQ2'23, Long-term debt: $5.0BQ2'23Q3'23, Cash and equivalents: $728MQ3'23, Long-term debt: $4.4BQ3'23Q4'23, Cash and equivalents: $537MQ4'23, Long-term debt: $4.1BQ4'23Q1'24, Cash and equivalents: $99MQ1'24, Long-term debt: $3.0BQ1'24Q2'24, Cash and equivalents: $265MQ2'24, Long-term debt: $3.0BQ2'24Q3'24, Cash and equivalents: $1.5BQ3'24, Long-term debt: $5.4BQ3'24Q4'24, Cash and equivalents: $1.5BQ4'24, Long-term debt: $5.3BQ4'24Q1'25, Cash and equivalents: $369MQ1'25, Long-term debt: $5.6BQ1'25Q2'25, Cash and equivalents: $647MQ2'25, Long-term debt: $5.1BQ2'25Q3'25, Cash and equivalents: $598MQ3'25, Long-term debt: $5.1BQ3'25Q4'25, Cash and equivalents: $532MQ4'25, Long-term debt: $5.1BQ4'25Q1'26, Cash and equivalents: $981MQ1'26, Long-term debt: $5.8BQ1'26Q2'26, Cash and equivalents: $142MQ2'26, Long-term debt: $5.9BQ2'26Q3'26, Cash and equivalents: $262MQ3'26, Long-term debt: $5.3BQ3'26$0$2B$4B$6BQ4'22, Cash and equivalents: $321MQ4'22, Long-term debt: $5.0BQ1'23, Cash and equivalents: $394MQ1'23, Long-term debt: $5.1BQ1'23Q2'23, Cash and equivalents: $1.9BQ2'23, Long-term debt: $5.0BQ3'23, Cash and equivalents: $728MQ3'23, Long-term debt: $4.4BQ3'23Q4'23, Cash and equivalents: $537MQ4'23, Long-term debt: $4.1BQ1'24, Cash and equivalents: $99MQ1'24, Long-term debt: $3.0BQ1'24Q2'24, Cash and equivalents: $265MQ2'24, Long-term debt: $3.0BQ3'24, Cash and equivalents: $1.5BQ3'24, Long-term debt: $5.4BQ3'24Q4'24, Cash and equivalents: $1.5BQ4'24, Long-term debt: $5.3BQ1'25, Cash and equivalents: $369MQ1'25, Long-term debt: $5.6BQ1'25Q2'25, Cash and equivalents: $647MQ2'25, Long-term debt: $5.1BQ3'25, Cash and equivalents: $598MQ3'25, Long-term debt: $5.1BQ3'25Q4'25, Cash and equivalents: $532MQ4'25, Long-term debt: $5.1BQ1'26, Cash and equivalents: $981MQ1'26, Long-term debt: $5.8BQ1'26Q2'26, Cash and equivalents: $142MQ2'26, Long-term debt: $5.9BQ3'26, Cash and equivalents: $262MQ3'26, Long-term debt: $5.3BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Labcorp Holdings Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue3,8103,7313,5383,5163,5643,5273,3453,329+6.9%
Cost of revenue2,7022,6192,5242,5232,5382,4812,3972,433+6.4%
Gross profit1,1081,1121,0149931,0251,046948896+8.1%
Research and development—————————
Selling, general and administrative611577551538553579546595+10.5%
Operating income402452381268397395326217+1.4%
Other income (expense)(5)(3)(13)(19)(2)(33)(1)16−184.2%
Pretax income—————————
Income tax6587422676666240−14.0%
Net income263299278165261238213143+0.7%
Diluted EPS ($)3.223.643.35—3.122.842.52—+3.2%
Diluted shares (millions)828283—848484——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Labcorp Holdings Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents2621429815325986473691,519−56.2%
Short-term investments—————————
Total current assets3,9663,8154,5594,0214,0794,0873,7904,807−2.8%
Total assets18,92518,53219,08718,39318,26218,06017,60418,379+3.6%
Total current liabilities2,8202,1252,6412,8242,6292,7172,0653,330+7.2%
Long-term debt5,2515,8585,8345,0855,0835,0775,5695,331+3.3%
Total liabilities10,0619,90910,3429,7569,5499,5719,28210,313+5.4%
Stockholders’ equity8,8488,6078,7298,6208,6978,4738,3078,052+1.7%
Shares outstanding (millions)8181828283838484—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 30, 2026.

Labcorp Holdings Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 30, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 4, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 1, 2025Q1 FY2025ended Mar 31, 2025filed Apr 29, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow56444619261438762119777+45.6%
Capital expenditures15213212112410778126112+42.1%
Free cash flow (CFO − capex)41231471490281543(107)665+47.0%
Depreciation and amortization183179173173171170167171+7.0%
Share repurchases03549822525200075−100.0%
Dividends paid5859615960606260−2.8%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Labcorp Holdings Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Mar 7, 2011FY2009ended Dec 31, 2009filed Feb 24, 2010FY2008ended Dec 31, 2008filed Aug 28, 2009FY2007ended Dec 31, 2007filed Aug 28, 2009
Revenue13,95213,00912,16211,86413,13613,97911,55511,33310,3089,5538,6806,0125,8085,6715,5425,0044,6954,5054,068
Cost of revenue9,9399,3858,7978,1558,1449,0268,3028,1577,2166,6995,7773,8093,5853,4223,2682,9062,7242,6312,377
Gross profit4,0133,6243,3653,7094,9924,9533,2533,1763,0922,8542,9032,2032,2232,2502,2752,0981,9711,8741,691
Research and development———————————————————
Selling, general and administrative2,2162,2302,0211,7631,6901,7291,6251,5711,4991,3461,6281,1981,1291,1151,1601,034959935809
Operating income1,3851,0877261,4373,0492,4451,3301,3261,3051,2719979109911,024948979936843777
Other income (expense)(55)6016(32)16(32)(3)(57)(228)(197)(271)(84)(75)(79)(82)(5)(4)(2)(1)
Pretax income———————————————————
Income tax230212189234690662280384(155)361287314340359333344329308326
Net income8777464181,2792,3771,5568248841,227712438511574583520558543465477
Diluted EPS ($)10.468.844.7713.9724.3913.64*7.17*7.40*10.15*5.86*3.74*5.08*5.37*5.15*4.39*4.54*4.28*3.57*3.38*
Diluted shares (millions)8484889298114*115*119*121*121*117*101*107*113*118*123*127*130*—

Balance sheet

Labcorp Holdings Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Mar 7, 2011FY2009ended Dec 31, 2009filed Feb 24, 2010FY2008ended Dec 31, 2008filed Aug 28, 2009FY2007ended Dec 31, 2007filed Aug 28, 2009
Cash and equivalents5321,5195373211,4731,32133842731743471658040440446715914922056
Short-term investments———————————————————
Total current assets4,0214,8073,7654,6255,3315,1252,9812,8352,7342,4792,6211,6931,4321,3921,0601,1449361,033—
Total assets18,39318,37916,72520,15520,38520,07218,04616,18516,67314,24714,1057,3026,9666,7956,1126,1884,8384,670—
Total current liabilities2,8243,3303,2253,0792,7833,0792,6561,8792,1861,8281,7019767361,0297331,1211,018547—
Long-term debt5,0855,3314,0555,0395,4175,4195,7905,9916,3455,3005,9402,6832,8892,1752,0861,8279771,601—
Total liabilities9,75610,3138,83510,04010,09110,61410,4599,1959,8488,7269,1454,4644,4554,0573,5883,7012,7322,860—
Stockholders’ equity8,6208,0527,87510,09710,2739,4377,6447,0486,8045,5184,9452,8212,4914,9452,5042,4662,1061,6881,725
Shares outstanding (millions)828484103*109*114*113*115*119*119*118*117*99*108*113*117*122*——

Cash flow statement

Labcorp Holdings Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 28, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 24, 2012FY2010ended Dec 31, 2010filed Mar 7, 2011FY2009ended Dec 31, 2009filed Feb 24, 2010FY2008ended Dec 31, 2008filed Aug 28, 2009FY2007ended Dec 31, 2007filed Aug 28, 2009
Operating cash flow1,6411,5861,3281,9563,1102,1351,4451,3051,4981,197982739819841856884862781710
Capital expenditures435490454429422382400380313279256204202174146126115157143
Free cash flow (CFO − capex)1,2061,0968741,5272,6881,7541,0459261,185918727536617668710758748624567
Depreciation and amortization681644577537577625577552533499458246230230231204195180163
Share repurchases4502501,0001,1001,6691004507003384402691,016517644338273334921
Dividends paid241243254195———————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$3M
5 sales by 4 insiders; officers and directors $3M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$13M
22 sales by 9 insiders; officers and directors $13M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 17, 2026Anderson Kerrii BDirectoropen-market sale10b5-13,000$318.02$954K6,563Aug 18, 2026
Aug 11, 2026Schechter Adam HPresident & CEO, Directoropen-market sale10b5-14,669$320.37$1M102,565Aug 12, 2026
Aug 4, 2026Summy Amy B.EVP, Chief Marketing Officeropen-market sale924$306.74$283K6,956Aug 6, 2026
Aug 3, 2026Wilkinson Peter JSVP, Chief Accounting Officeropen-market sale82$309.22$25K1,770Aug 5, 2026
Aug 3, 2026Wilkinson Peter JSVP, Chief Accounting Officeroption exercise1,338$209.25$280K3,108Aug 5, 2026
Aug 3, 2026Wilkinson Peter JSVP, Chief Accounting Officeropen-market sale1,338$309.23$414K1,770Aug 5, 2026
Jul 2, 2026Kyle Kathryn WEVP, Chief Legal Officeropen-market sale10b5-192$286.19$26K3,904Jul 6, 2026
Jul 2, 2026Vaughn Bryan TEVP and President, Diagnosticsopen-market sale10b5-1234$286.19$67K6,746Jul 6, 2026
Jul 1, 2026Kyle Kathryn WEVP, Chief Legal Officeroption exercise256——4,069Jul 6, 2026
Jul 1, 2026Kyle Kathryn WEVP, Chief Legal Officertax withholding73$283.88$21K3,996Jul 6, 2026
Jul 1, 2026Vaughn Bryan TEVP and President, Diagnosticsoption exercise327——7,073Jul 6, 2026
Jul 1, 2026Vaughn Bryan TEVP and President, Diagnosticstax withholding93$283.88$26K6,980Jul 6, 2026
Jun 8, 2026Kyle Kathryn WEVP, Chief Legal Officeropen-market sale10b5-1762$263.89$201K3,813Jun 10, 2026
May 11, 2026Schechter Adam HPresident & CEO, Directoropen-market sale10b5-15,903$254.50$2M107,234May 13, 2026
Mar 27, 2026Wilkinson Peter JSVP, Chief Accounting Officeropen-market sale10b5-11,633$267.05$436K1,852Mar 30, 2026
Mar 27, 2026Meltzer Jonathan CEVP, Operationsopen-market sale10b5-1839$267.05$224K3,620Mar 30, 2026
Mar 27, 2026Wilkinson Peter JSVP, Chief Accounting Officeropen-market sale10b5-11,633$267.05$436K1,852Mar 30, 2026
Mar 27, 2026Meltzer Jonathan CEVP, Operationsopen-market sale10b5-1839$267.05$224K3,620Mar 30, 2026
Mar 26, 2026Schechter Adam HPresident & CEO, Directortax withholding26,106$268.38$7M113,137Mar 30, 2026
Mar 26, 2026Schechter Adam HPresident & CEO, Directoraward58,470$0.00—139,243Mar 30, 2026
Mar 26, 2026Graham Anita ZEVP, CHROaward6,604$0.00—8,064Mar 30, 2026
Mar 26, 2026Graham Anita ZEVP, CHROtax withholding2,879$268.38$773K5,185Mar 30, 2026
Mar 26, 2026Schroeder Mark SEVP, Pres Diagnostics & COOtax withholding1,468$268.38$394K12,677Mar 30, 2026
Mar 26, 2026Schroeder Mark SEVP, Pres Diagnostics & COOaward2,968$0.00—14,145Mar 30, 2026
Mar 26, 2026Schroeder Mark SEVP, Pres Diagnostics & COOtax withholding4,600$268.38$1M11,177Mar 30, 2026

Full insider history for Labcorp Holdings Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
LABCORP HOLDINGS INC., CIK 920148 on EDGAR
Extract generated
November 1, 2026
Withheld
11 line-years whose four quarters do not sum to the filed year: other income FY2012, other income FY2013, revenue FY2015, gross profit FY2016, income tax FY2017, net income FY2019, buybacks FY2022, cost of revenue FY2022, gross profit FY2022, operating income FY2022, revenue FY2022
Repaired
15 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: cost of revenue FY2014, gross profit FY2014, income tax FY2014, net income FY2014, operating income FY2014, opex sga FY2014, other income FY2014, revenue FY2014, income tax FY2015, income tax FY2016, revenue FY2016, income tax FY2018, other income FY2019, other income FY2020, other income FY2021
XBRL concepts behind each line

Income statement

Revenue: Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: not filed
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/LH.json